文献速递临床试验与 GCP

平衡明胶溶液与平衡电解质溶液早期目标控制性血浆容量替代治疗严重脓毒症/脓毒性休克的疗效与安全性:GENIUS研究方案

Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial : GENIUS-Gelatine use in ICU and sepsis.
PubMed 文献 · Trials · 2021-06-02

本研究为前瞻性、随机、对照、双盲、国际多中心IV期试验,计划纳入608例严重脓毒症/脓毒性休克低血容量患者,比较明胶-晶体液1:1方案与纯晶体液方案进行目标控制性血浆容量替代治疗的疗效与安全性,主要结局为达到血流动力学稳定的时间。

要点

  • 严重脓毒症/脓毒性休克患者早期目标控制性血浆容量替代治疗中,明胶-晶体液方案与纯晶体液方案的疗效与安全性尚缺乏大型试验证据。
  • 目标控制性液体管理仅对容量反应性患者补液,可能减少血流动力学稳定患者的液体过负荷风险。
  • 主要结局为达到血流动力学稳定的时间,安全性评估持续28天或至ICU出院。

核心结论

  • 本研究旨在生成证据,明确明胶-晶体液方案与纯晶体液方案在严重脓毒症/脓毒性休克低血容量患者中达到血流动力学稳定的有效性。

研究设计与样本

  • 前瞻性、随机、对照、双盲、国际多中心IV期试验,两个平行组,计划在欧洲ICU进行。
  • 计划纳入608例严重脓毒症/脓毒性休克低血容量患者,随机接受明胶-晶体液方案(Gelaspan® 4%与Sterofundin® ISO按1:1比例)或纯晶体液方案(Sterofundin® ISO)。
  • 血浆容量替代治疗为目标控制性,仅对容量反应性患者补液,容量反应性通过被动抬腿试验或液体负荷试验评估。

关键数值与推荐

  • 主要结局为达到血流动力学稳定所需时间。
  • 次要结局为两种方案的安全性和有效性,每日评估持续28天或至ICU出院(以先发生者为准)。
  • 随访计划在第28天和第90天进行。

临床怎么用

  • 对于严重脓毒症/脓毒性休克低血容量患者,目标控制性血浆容量替代治疗仅对容量反应性患者补液,避免对已血流动力学稳定患者补液。
  • 明胶-晶体液方案与纯晶体液方案的选择需等待本试验结果提供证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sepsis is associated with capillary leakage and vasodilatation and leads to hypotension and tissue hypoperfusion. Early plasma volume replacement is required to achieve haemodynamic stability (HDS) and maintain adequate tissue oxygenation. The right choice of fluids to be used for plasma volume replacement (colloid or crystalloid solutions) is still a matter of debate, and large trials investigating the use of colloid solutions containing gelatine are missing. This study aims to investigate the efficacy and safety of plasma volume replacement using either a combined gelatine-crystalloid regime (1:1 ratio) or a pure crystalloid regime. METHODS: This is a prospective, controlled, randomized, double-blind, international, multicentric phase IV study with two parallel groups that is planned to be conducted at European intensive care units (ICUs) in a population of patients with hypovolaemia in severe sepsis/septic shock. A total of 608 eligible patients will be randomly assigned to receive either a gelatine-crystalloid regime (Gelaspan® 4% and Sterofundin® ISO, B. Braun Melsungen AG, in a 1:1 ratio) or a pure crystalloid regime (Sterofundin® ISO) for plasma volume replacement. The primary outcome is defined as the time needed to achieve HDS. Plasma volume replacement will be target-controlled, i.e. fluids will only be administered to volume-responsive patients. Volume responsiveness will be assessed through passive leg raising or fluid challenges. The safety and efficacy of both regimens will be assessed daily for 28 days or until ICU discharge (whichever occurs first) as the secondary outcomes of this study. Follow-up visits/calls will be scheduled on day 28 and day 90. DISCUSSION: This study aims to generate evidence regarding which regimen-a gelatine-crystalloid regimen or a pure crystalloid regimen-is more effective in achieving HDS in critically ill patients with hypovolaemia. Study participants in both groups will benefit from the increased safety of target-controlled plasma volume replacement, which prevents fluid administration to already haemodynamically stable patients and reduces the risk of harmful fluid overload. TRIAL REGISTRATION: The European clinical trial database EudraCT 2015-000057-20 and the ClinicalTrials.gov Protocol Registration and Results System ClinicalTrials.gov NCT02715466 . Registered on 17 March 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Marx G, Zacharowski K, Ichai C, et al. Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial : GENIUS-Gelatine use in ICU and sepsis. Trials. 2021. PMID: 34078421. doi:10.1186/s13063-021-05311-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。